# EDGAR Filing Document

**Accession Number:** 0001979005
**File Stem:** 0001493152-26-024600
**Filing Date:** 2026-5
**Character Count:** 10781
**Document Hash:** 1fe6a9f6aa3610a4dfe176a9a2641e0b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-024600.hdr.sgml**: 20260520

**ACCESSION NUMBER**: 0001493152-26-024600

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260519

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260520

**DATE AS OF CHANGE**: 20260520

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aimei Health Technology Co., Ltd.
- **CENTRAL INDEX KEY:** 0001979005
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41880
- **FILM NUMBER:** 261003943

**BUSINESS ADDRESS:**
- **STREET 1:** 10 EAST 53RD STREET
- **STREET 2:** SUITE 3001
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 34 678 035200

**MAIL ADDRESS:**
- **STREET 1:** 10 EAST 53RD STREET
- **STREET 2:** SUITE 3001
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

?xml version='1.0' encoding='ASCII'?

**United States**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**May 19, 2026**

Date of Report (Date of earliest event reported)

**<u>AIMEI HEALTH TECHNOLOGY CO., LTD</u>**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-41880** | **N/A** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **10 East 53rd Street, Suite 3001**<br> **New York, NY** | **10022** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**86-13758131392**

Registrant's telephone number, including area code

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Ordinary Shares, par value $0.0001 per share | AFJK | The Nasdaq Stock Market LLC |
| Rights, exchangeable into one-fifth of one Ordinary Share | AFJKR | The Nasdaq Stock Market LLC |
| Units, each consisting of one Ordinary Share and one Right | AFJKU | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On May 19, 2026, Aimei Health Technology Co., Ltd (the "***Company***") received a notice (the "***Notice***") from the Listing Qualifications Department (the "***Staff***") of The Nasdaq Stock Market LLC ("***Nasdaq***"), notifying the Company that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 (the ***"Quarterly Report***"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the "***SEC***"). The Quarterly Report was due on May 15, 2026.

The Notice has no immediate effect on the listing or trading of the Company's securities on Nasdaq. However, if the Company fails to timely regain compliance with the Listing Rule, the Company's securities will be subject to delisting from Nasdaq.

Under the Nasdaq rules, the Company has 60 calendar days from the date of the Notice either to file the Quarterly Report or to submit a plan to Nasdaq to regain compliance with Nasdaq's listing rules. If a plan is submitted and accepted, the Company could be granted up to 180 calendar days from the Quarterly Report's due date to regain compliance. If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.

While the Company can provide no assurances as to timing, the Company is working diligently to complete and file the Quarterly Report and expects to regain compliance with the Listing Rule.

On May 20, 2026, the Company issued a press release in accordance with Nasdaq Listing Rule 5810(b) announcing that it had received the Notice. A copy of the press release is attached hereto as Exhibit 99.1.

***Cautionary Statement Regarding Forward-Looking Statements***

*This Current Report on Form 8-K may contain "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements provide management's current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Statements containing words such as "believe," "intend," "plan," "may," "expect," "should," "could," "anticipate," "estimate," "predict," "project," or their negatives, or other similar expressions of a future or forward-looking nature, generally should be considered forward-looking statements. The forward-looking statements in this Current Report are based on management's current expectations and assumptions about future events that involve inherent risks and uncertainties. While the Company considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks and uncertainties, most of which are difficult to predict and many of which are beyond the Company's control. The Company undertakes no obligation to review or update any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.*

**Item 9.01 Exhibits.**

(d) *Exhibits*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release dated May 20, 2026](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 20, 2026

---

| | |
|:---|:---|
| **Aimei Health Technology Co., Ltd** | **Aimei Health Technology Co., Ltd** |
| By: | */s/ Junheng Xie* |
| Name: | Junheng Xie |
| Title: | Chief Executive Officer and Director |
|  | (Principal Executive Officer) |

---

## Exhibit 99.1

**Exhibit 99.1**

**AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED QUARTERLY REPORT**

New York, NY – May 20, 2026 – Aimei Health Technology Co., Ltd (the "Company") (Nasdaq: AFJK) today announced that on May 19, 2026, it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the "Quarterly Report") with the U.S. Securities and Exchange Commission (the "SEC"), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"). The Quarterly Report was due on May 15, 2026.

The Notice has no immediate effect on the listing or trading of the Company's securities on Nasdaq. However, if the Company fails to timely regain compliance with the Listing Rule, the Company's securities will be subject to delisting from Nasdaq.

Under Nasdaq rules, the Company has 60 calendar days from the date of the Notice to either file the Quarterly Report or submit a plan to Nasdaq to regain compliance with Nasdaq's listing rules. If a plan is submitted and accepted, the Company may be granted up to 180 calendar days from the Quarterly Report's due date to regain compliance. If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.

The Company is working diligently to complete and file the Quarterly Report and expects to regain compliance with the Listing Rule.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

**About Aimei Health Technology Co., Ltd**

Aimei Health Technology Co., Ltd is a blank check company incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the Company intends to pursue prospective targets focused on healthcare innovation.

**Forward-Looking Statements**

This press release contains "forward-looking" statements within the meaning of the federal securities laws. These statements are based on management's current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

For investor and media inquiries, please contact:

Aimei Health Technology Co., Ltd

10 East 53rd Street, Suite 3001

New York, NY 10022

Attention: Junheng Xie

Email: <u>Xiejunheng@aimeihealth.com</u>